http://www.law360.com/ Latest articles for organization: Bristol-Myers Squibb Copyright 2009 Portfolio Media, Inc. en-US http://www.law360.com/images/headings/logo.gif http://www.law360.com/ http://www.law360.com/articles/135646 A Pennsylvania jury has ruled that two Pfizer Inc. units are on the hook for at least $6.3 million in compensatory damages to an Illinois woman who developed breast cancer after she began taking popular menopause drugs Prempro and Provera. http://www.law360.com/articles/135646 http://www.law360.com/articles/135054 The U.S. Food and Drug Administration has announced labeling changes to Plavix, manufactured by Sanofi-Aventis SA and Bristol-Myers Squibb Co., to reflect new data showing that simultaneously taking the heartburn treatment Prilosec can sharply reduce the effects of the blockbuster blood thinner. http://www.law360.com/articles/135054 http://www.law360.com/articles/134313 Bristol-Myers Squibb Co. has said it plans to split off its 83 percent stake in infant-formula maker Mead Johnson Nutrition Co., a move the drugmaker said will allow it to focus on its biopharmaceutical business. http://www.law360.com/articles/134313 http://www.law360.com/articles/132433 While the verdict officially remains under wraps, word is spreading that a Pennsylvania jury has ordered Pfizer Inc. to fork over $75 million in punitive damages to a woman who developed invasive breast cancer after she began taking the popular menopause drug Prempro. http://www.law360.com/articles/132433 http://www.law360.com/articles/131977 Calling the inquiries “irrelevant and inappropriate,” Sanofi-Aventis SA and Bristol-Myers Squibb Co. have sought to snuff out six subpoenas issued by generic-drug maker Apotex Inc. in connection with settlement amount determinations in a patent infringement dispute over blockbuster blood thinner Plavix. http://www.law360.com/articles/131977 http://www.law360.com/articles/131836 Apotex Inc.'s legal dispute with Sanofi-Aventis over blood-thinning drug Plavix has hit a dead end, with the U.S. Supreme Court refusing to hear the generic-drug maker's arguments over whether substances produced by so-called obvious-to-try experiments should be patentable. http://www.law360.com/articles/131836 http://www.law360.com/articles/130536 In a one-two punch to Pfizer Inc., a Philadelphia jury has reportedly awarded punitive damages in addition to $3.7 million in compensatory damages to a woman who developed invasive breast cancer after she began taking Prempro, which is made by the company’s Wyeth unit. http://www.law360.com/articles/130536 http://www.law360.com/articles/130210 A federal court ruled Friday that two generic-drug makers violated patents held by Allergan Inc. for glaucoma treatments using brimonidine. http://www.law360.com/articles/130210 http://www.law360.com/articles/126342 Generic-drug maker Apotex Corp. has launched a new attack on Bristol-Myers Squibb Co. and Sanofi-Aventis' patent for blood-thinning drug Plavix, arguing in a new suit that it is unenforceable because Bristol-Myers and Sanofi breached a 2006 settlement with Apotex over the patent. http://www.law360.com/articles/126342 http://www.law360.com/articles/124783 A federal judge has dismissed a $2.3 billion antitrust lawsuit accusing 16 pharmaceutical manufacturers and a group of drug distributors of conspiring to keep a Long Island, N.Y.-based secondary wholesaler out of business. http://www.law360.com/articles/124783 http://www.law360.com/articles/124172 Less than a week after asking a court to dismiss Bristol-Myers Squibb Co. from a suit, the state of Arizona has revealed that the parties have reached a $900,000 settlement that will put to rest allegations that the pharmaceutical giant schemed to artificially boost average wholesale drug prices. http://www.law360.com/articles/124172 http://www.law360.com/articles/122825 The state of Arizona has asked a court to dismiss Bristol-Myers Squibb Co. from multidistrict litigation accusing a number of pharmaceutical companies of scheming to artificially boost average wholesale drug prices, following a settlement agreement between the two parties. http://www.law360.com/articles/122825 http://www.law360.com/articles/121652 Abbott Laboratories has asked a judge to throw out four recently amended complaints filed by pharmacies, wholesale direct drug purchasers and rival drug manufacturers alleging Abbott illegally jacked up the prices of its market-dominating HIV drugs, calling the complaints “a vain attempt to plead around” recent antitrust case law. http://www.law360.com/articles/121652 http://www.law360.com/articles/120843 Cadence Pharmaceuticals Inc. has registered for an aggregate initial offering of up to $100 million in securities with the U.S. Securities and Exchange Commission. http://www.law360.com/articles/120843 http://www.law360.com/articles/117786 A federal appeals court has rejected a bid for an en banc rehearing of its decision to limit a settlement to $10 million in a class action alleging that Abbott Laboratories illegally jacked up the prices of its market-dominating HIV drug Norvir, sticking to its finding that the plaintiffs failed to state a claim in light of recent case law. http://www.law360.com/articles/117786 http://www.law360.com/articles/117241 The U.S. Patent and Trademark Office has granted generic-drug maker Apotex Corp.'s request for re-examination of Sanofi-Aventis' patent for blood-thinner Plavix, as Apotex fights to break down intellectual property barriers to its attempt to market a generic version of the blockbuster drug. http://www.law360.com/articles/117241 http://www.law360.com/articles/116561 Rite Aid Corp., CVS Pharmacy Inc. and several other pharmacy chains have filed a second amended complaint in their antitrust action against Abbott Laboratories alleging the drugmaker illegally jacked up the prices of its market-dominating HIV medications, following an appeals court ruling that a similar class action against Abbott failed to state a valid claim in light of recent case law. http://www.law360.com/articles/116561 http://www.law360.com/articles/116228 Sanofi-Aventis has reached a deal with Watson Pharmaceuticals Inc. in a long-standing patent infringement suit over Watson’s attempt to market a generic version of the blockbuster blood thinner Plavix. http://www.law360.com/articles/116228 http://www.law360.com/articles/115501 Following an appeals court ruling for Abbott Laboratories in a class action accusing the company of jacking up the price of its HIV medication Norvir, a federal judge has granted final approval to a settlement under which the pharmaceutical company will donate $7 million to AIDS charities and pay an additional $3 million to indirect purchasers. http://www.law360.com/articles/115501 http://www.law360.com/articles/113763 Generic-drug maker Apotex Inc. has asked the U.S. Supreme Court to weigh in on its patent dispute with Bristol-Myers Squibb Co. and Sanofi-Aventis, makers of the blockbuster blood-thinning drug Plavix, saying substances produced by “obvious to try” experiments should not be patentable. http://www.law360.com/articles/113763